



EAPC
European Association
of Preventive Cardiology

The European Association of Preventive Cardiology (EAPC) presents

2018 EuroPrevent

European Congress on Preventive Cardiology

LJUBLJANA
SLOVENIA

**19-21
APRIL**



PRELIMINARY PROGRAMME
February 2018

#europrevent
www.escardio.org/europrevent



ESC
European Society
of Cardiology

EuroPrevent Congress

- Multi-faceted educative, practical and informative programme
- Latest science on key topics in high quality forums
- Network with world renowned experts
- Scientific exchange to help you deliver the very best primary and secondary prevention
- Learn across the full scope of preventive cardiology from Prevention, Epidemiology & Population Science to Cardiac Rehabilitation and Exercise, Basic & Translational Research, and Sports Cardiology.

The place to get essential updates and guidance for your practice

Congress theme:

Evidence based cardiovascular prevention A lifelong endeavour

- Full health maintenance from before birth to golden years
- Diverse aspects such as: genetics, nutrition, diagnostics, exercise, pharmacological treatment, clinical advances and more
- Socio-economic factors, risk factors including lipids and hypertension

European Association of Preventive Cardiology (EAPC)



EAPC

European Association
of Preventive Cardiology



European Society of Cardiology

EAPC is a registered branch of the European Society of Cardiology, representing over 6200 health professionals.

Our mission: To promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.

Key dates:

Abstract Submission deadline:
09 November 2017

Early Registration deadline:
08 February 2018

Late Registration deadline:
15 March 2018





08:30 - 10:00 Case-based Symposium

Chairpersons: Vassilios VASSILIOU (Cambridge, United Kingdom), Maja-Lisa LOCHEN (Tromsø, Norway)

Identifying and assessing risk for cerebrovascular disease - Case demonstrations

08:30 Embolic stroke of undetermined source: how to screen for atrial fibrillation?

Panagiota Anna CHOUSOU (Cambridge, United Kingdom)

08:52 Definition of atrial fibrillation from device recordings and indications for anticoagulation.

09:15 Prevention of atrial fibrillation: optimal blood pressure control in different clinical settings.

Piotr JANKOWSKI (Krakow, Poland)

09:37 Atrial fibrillation in patients after acute coronary syndromes and stent implantation: individualisation of dual antithrombotic treatment anticoagulation.

Christina CHRYSOHOOU (Athens, Greece)

Learning Objectives: Identification of arrhythmia in cryptogenic stroke.

Evaluation of device recordings for arrhythmia detection and optimal use for anticoagulation in stroke.

Appreciation of cardiovascular risk factors that can increase the incidence of atrial fibrillation.

Personalisation of medical therapy in patients with atrial fibrillation and acute coronary syndromes.

08:30 - 10:00 Symposium

Chairpersons: Trine KARLSEN (Bodo, Norway), Paul LEESON (Oxford, United Kingdom)

Relative effect of genetic risk and lifestyle in cardiovascular disease

08:30 The combined effect of genetic risk, diet and physical activity on the risk of cardiovascular diseases.

08:52 The combined effect of genetic risk, diet and physical activity on obesity and incidence of diabetes.

09:15 Effect of family history and lifestyle change on incidence of diabetes.

Matti UUSITUPA (Kuopio, Finland)

09:37 Study methods for combined effects of genetic risk and lifestyle.

Learning Objectives: Genome-wide association studies have identified a multitude of single nucleotide polymorphisms associated with cardiovascular diseases. At the same time, lifestyle is a powerful modifier of cardiovascular risk. This session discusses the interaction between genetically determined and Lifestyle-mediated cardiovascular risk.

08:30 - 10:00 Symposium

Chairpersons: Nico BRUINING (Rotterdam, Netherlands), Gianfranco PARATI (Milano, Italy)

**Evidence base for cardiac telerehabilitation
and its core components in different cardiac patient populations**

08:30 EU-CaRe: assessing the efficacy of telerehabilitation in the elderly cardiac patient.

Matthias WILHELM (Bern, Switzerland)

08:52 SmartCare-CAD: assessing the (cost-) effectiveness of web-based telerehabilitation in coronary artery disease.

Rutger BROUWERS (Eindhoven, Netherlands)

09:15 eEduHeart I: the role of E-Learning and remote cardiac patient education.

Ines FREDERIX (Rotselaar, Belgium)

09:37 Remote-CR: assessing the value of remote physical exercise monitoring.

Jonathan RAWSTORN (Melbourne, New Zealand)

08:30 - 10:00 Young Investigator Awards Abstracts

Young Investigator Award session I - Sport Cardiology

Learning Objectives: Six abstracts selected for their outstanding quality. Finalists will be presenting their research in front of an appreciative audience, chairpersons and judges expert in the topic. A winner will be awarded a diploma and a prize of €500.

11:00 - 12:30 Symposium

Chairpersons: Christine GRAF (Cologne, Germany), Monica TIBERI (Pesaro, Italy)

Beyond medicines. Evidence of relaxation techniques for cardiovascular prevention and management

11:00 Mind-body practices.

Jari Antero LAUKKANEN (Jyväskylä, Finland)

11:22 Sauna.

Jean-Paul SCHMID (Barmelweid, Switzerland)

11:45 Tai chi.

12:07 Yoga.

Kushal MADAN (New Delhi, India)

Learning Objectives: Know the pros and cons of non-medical management of cardiovascular risk factors

11:00 - 12:30 Symposium

Chairpersons: Hareld KEMPS (Den Bosch, Netherlands), Nicolle KRAENKEL (Berlin, Germany)

It doesn't always work. Responders and non-responders in lifestyle interventions.

11:00 What can we learn from failed lifestyle interventions?

Matthias WILHELM (Bern, Switzerland)

11:22 Is it in the genes? Genetic determination of exercise effects.

Emeline VAN CRAENENBROECK (Edegem, Belgium)

11:45 Why some people benefit more than others. What differentiates responders from non-responders in lifestyle intervention trials?

Trine KARLSEN (Bodo, Norway)

12:07 It works only if you do it! How to improve adherence in life style-based intervention programmes.

Jan KEENAN (Oxford, United Kingdom)

Learning Objectives: Lifestyle interventions can be a powerful tool to reduce cardiovascular risk. However, not all patients can benefit from exercise or diet-based programmes. This session discusses reasons, including the impact of the genetic background, motivation and interaction with pharmacological therapy.

11:00 - 12:30 Symposium

Cardiovascular consequences of drugs and substance abuse in athletes

11:00 Cardiovascular effect of anabolic steroids in athletes.

Georgios CHRISTOU (Preveza, Greece)

11:22 Proarrhythmic effect of prescribed substances in physically active patients.

11:45 Chemotherapeutic drugs and cardiac function. The contribution of exercise to maintain physical performance.

Chiara LESTUZZI (Aviano, Italy)

12:07 Energy drinks and stimulating substances in young and fit individuals.

Paolo Emilio ADAMI (Rome, Italy)

Learning Objectives: The objective of the session is to present the most common cardiovascular side effects of prescribed drugs, illicit or freely available substances in athletes, patients or young and fit individuals, that physician might deal with in their daily practice.

11:00 - 12:30 Rapid Fire Abstract

Rapid Fire Session I

Learning Objectives: Fast-paced and interactive session including presentation of 8 topic related abstracts. Each presentation will be followed by questions and discussions with the audience moderated by the Chairpersons.

12:45 – 13:45 *Satellite Symposium*

Chairpersons: Diederick E GROBBEE (Utrecht, Netherlands), John Eric DEANFIELD (London, United Kingdom)

Subtitle: Sponsored by PACE-CME: Physicians' Academy for Cardiovascular Education

**Preventing cardiovascular disease in patients with T2DM:
how to apply novel outcome data with GLP-1 ra to clinical practice.**

12:45 Introduction - Preventing cardiovascular disease in patients with T2DM: how to apply novel outcome data with GLP-1 ra to clinical practice.

Diederick E GROBBEE (Utrecht, Netherlands)

12:50 The cardiovascular challenge for primary care in diabetes.

Richard HOBBS (Oxford, United Kingdom)

13:05 Diabetes: how to reduce risk from a cardiovascular perspective?

John Eric DEANFIELD (London, United Kingdom)

13:25 Practical management of cardiovascular risk: lessons from latest diabetes trials.

Lars RYDEN (Stockholm, Sweden)

13:40 Discussion - Preventing cardiovascular disease in patients with T2DM: how to apply novel outcome data with GLP-1 ra to clinical practice.

Learning Objectives: • Understand the relation between type 2 diabetes mellitus (T2DM) & Cardiovascular Disease. • Identify the needs for novel approaches targeting T2DM in cardiovascular prevention. • Explore results from recent cardiovascular outcome trials (CVOT) in T2DM. • Discuss potential mechanisms and multifactorial effects of Glucagon-like peptide-1 receptor agonist (GLP-1 ra) contributing to cardiovascular benefits. • Review results from recent GLP1 ra outcomes trials, such as LEADER on CV and microvascular outcomes. • Discuss practical implications from recent CVOTs on treatment and prevention strategies in patients with CV risk and T2DM.

12:45 – 13:45 *Satellite Symposium*

Chairpersons: Zlatko FRAS (Ljubljana, Slovenia)

Subtitle: Sponsored by Krka, d. d., Novo mesto

The power of synergy.

12:45 Introduction - The power of synergy.

Zlatko FRAS (Ljubljana, Slovenia)

12:50 Challenges of concurrent treatment of dyslipidemia and hypertension.

Ian Maklim GRAHAM (Wicklow, Ireland)

13:05 Clinical benefits of concurrent treatment of dyslipidemia and hypertension.

Borut JUG (Ljubljana, Slovenia)

13:20 From science to practice: a patient case.

Maciej BANACH (Lodz, Poland)

13:35 Conclusion - The power of synergy.

Zlatko FRAS (Ljubljana, Slovenia)

Learning Objectives: - to recognise main gaps in treatment of dyslipidemia and hypertension in clinical practice. - to learn about main clinical benefits of concurrent treatment of dyslipidemia and hypertension. - to learn through presented clinical case how to apply solutions in clinical practice.

14:00 - 15:30 Symposium

Chairpersons: Luigi PALMIERI (Rome, Italy), Eva PRESCOTT (Copenhagen, Denmark)

Sex differences in cardiovascular disease: the Full Spectrum

14:00 Sex differences in prevention and prognosis of cardiovascular disease: an epidemiological perspective
Maryam KAVOUSI (Rotterdam, Netherlands)

14:22 Sex-specific diagnosis and management of cardiovascular disease: a clinical perspective
Eva SWAHN (Linköping, Sweden)

14:45 Cardiovascular disease treatment: a sex-specific pattern for adverse cardiovascular drug effects?
Jeanine ROETERS VAN LENNEP (Rotterdam, Netherlands)

15:07 Strategies to improve cardiovascular health in women.
Marco STRAMBA-BADIALE (Milan, Italy)

Learning Objectives: Cardiovascular disease (CVD) continues to be the leading cause of death for women. The average lifetime risk of developing CVD in women at 50 years of age is ≈40%, and this percentage rises as the number of risk factors increases. To reduce CVD mortality and the overall CVD burden, focus on both primary and secondary prevention of CVD is necessary. This session will give an overview of traditional and novel risk factors, diagnosis, treatment, and prognosis of cardiovascular disease among women.

14:00 - 15:30 Symposium

Chairpersons: Goran KRSTACIC (Zagreb, Croatia), Mamas MAMAS (Stockport, United Kingdom)

**Applying e-Health strategies to promote
and improve patient engagement in cardiovascular disease**

14:00 Patient engagement in establishing patient-centered cardiovascular care.
Enrico Gianluca CAIANI (Milano, Italy)

14:22 PATHway: technology enabled remote behavioural change
Roselien BUYS (Leuven, Belgium)

14:45 Evidence on the efficacy of e-Health strategies to improve patient engagement
Polychronis E DILAVERIS (Athens, Greece)

15:07 Challenges for large-scale e-Health deployment in cardiology and how to address these
Ekaterini LAMBRINOU (Limassol, Cyprus)

16:30 - 18:00 Symposium

Chairpersons: Olga BARNA (Kyiv, Ukraine), Jean-Claude BARTHELEMY (Saint-Etienne, France)

Sleep as a risk factor for cardiovascular disease

16:30 Sleep duration and cardiovascular risk: what's the evidence from observational studies?
Francesco CAPPUCCIO (Leamington Spa, United Kingdom)

16:52 Sleep apnea and cardiovascular risk.
Raphael HEINZER (Lausanne, Switzerland)

17:15 Mechanisms of sleep disturbance and cardiovascular risk.
Jean-Philippe EMPANA (Paris, France)

17:37 What can we do to improve sleep quantity and sleep quality?

Learning Objectives: The importance of sleep is more and more recognized in cardiovascular disease prevention. This session will give an overview of the risk associated with lack of sleep, the mechanisms involved, and ways to improve sleep quality and quantity.

16:30 - 18:00 Symposium

Chairpersons: Hein HEIDBUCHEL (Antwerp, Belgium), Antonio PELLICCIA (Rome, Italy)

**Safety and efficacy of old and new technologies
for the prevention of sudden death in athletes**

16:30 Dynamics of fibrillation and defibrillation during physical activity: implications for participation in competitive sports of athletes implanted with an ICD.

Mark LINK (Dallas, United States of America)

16:52 CT and coronary calcium to identify risk of SCD due to coronary disease.

Mats BORJESSON (Vastra Frolunda, Sweden)

17:15 S-ICD in patients with HCM.

17:37 Exercise prescription in patients with implantable devices.

Learning Objectives: The session aims at providing information and data from international electrophysiology centers with an extensive experience in trans-venous (TV-ICD) and sub-cutaneous cardioverter defibrillators (S-ICD) implantation in physically active individuals.

16:30 - 18:00 Young Investigator Awards Abstracts

Young investigator award session II - Cardiac Rehabilitation

Learning Objectives: Six abstracts selected for their outstanding quality. Finalists will be presenting their research in front of an appreciative audience, chairpersons and judges expert in the topic. A winner will be awarded a diploma and a prize of €500.

18:15 – 20:00 Special Event

Inaugural session & Networking Reception

An opportunity to hear from and meet up with the EAPC leadership.





08:30 - 10:00 Symposium

Chairpersons: Pedro MARQUES-VIDAL (Lausanne, Switzerland), Grethe S TELL (Bergen, Norway)

Diet and CVD: what's new?

08:30 Salt: update on impact of salt on CVD burden and global initiatives to lower salt intake.

Francesco CAPPUCCIO (Leamington Spa, United Kingdom)

08:52 Sugar: recent developments and ways to reduce sugar intake to prevent obesity and CVD.

09:15 Fatty acids: new insights in the ongoing story of saturated fatty acids.

Ivonne SLUIJS (Utrecht, Netherlands)

09:37 Improving dietary habits: what works?

Martin O'FLAHERTY (Liverpool, United Kingdom)

Learning Objectives: By attending this session, participants leave with up to date knowledge on the importance of salt, Sugar and fatty acids on cardiovascular diseases. These are topics that remain controversial.

08:30 - 10:00 Symposium

Chairpersons: Jana BRGULJAN (Ljubljana, Slovenia), Kai SAVONEN (Kuopio, Finland)

Exercise and blood pressure in cardiovascular prevention: what can be achieved?

08:30 Blood pressure behavior during exercise: physiologic control and pathophysiologic mechanisms.

Josef NIEBAUER (Salzburg, Austria)

08:52 Exercise, blood pressure and cardiovascular health: role of vascular biomarkers.

Henner HANSSEN (Basel, Switzerland)

09:15 Target blood pressure and clinical outcome: what can be achieved by exercise?

Paul LEESON (Oxford, United Kingdom)

09:37 Recommendations for exercise prescription in hypertension: an update.

Marco GUAZZI (San Donato Milanese, Italy)

Learning Objectives: Exercise therapy in hypertension is an important treatment modality in cardiovascular prevention, both for primary and secondary prevention. The ESH/ESC Guidelines for the management of arterial hypertension include regular physical exercise as a treatment strategy. However, essential questions remain on how much exercise is needed to reduce BP in hypertension, how and to what extent exercise affects mortality in hypertensive patients and how exercise can be individually prescribed to optimize therapy strategies in manifest hypertension and in the primary prevention of hypertension. This session aims at giving an update on these issues based on the current literature and offers discussions on practical recommendations.

08:30 - 10:00 *Symposium*

Chairpersons: Haruki ITOH (Tokyo, Japan)

Subtitle: Joint Session with the Japanese Association of Cardiac Rehabilitation 2018

Cardiac Rehabilitation: From hospital to community

08:30 Cardiac rehabilitation in Japan: Methods and Results.

Shigeru MAKITA (Hidaka, Japan)

08:52 Cardiac Rehabilitation in Europe: Methods and Results.

Ana ABREU (Lisboa, Portugal)

09:15 Evidence of cardiac rehabilitation in heart failure with reduced ejection fraction.

09:37 Evidence of cardiac rehabilitation in heart failure with preserved ejection fraction.

Shinji SATO (Tokorozawa, Japan)

Learning Objectives: In the yearly joint session the cardiac rehabilitation picture in Europe and Japan will be compared.

Recent data about the feasibility and effectiveness of training modalities in different settings - residential and community-based - will be presented.

08:30 - 10:00 *Young Investigator Awards Abstracts*

Young investigator award session III - Exercise Basic & Translational Research (EBTR)

Learning Objectives: Six abstracts selected for their outstanding quality. Finalists will be presenting their research in front of an appreciative audience, chairpersons and judges expert in the topic. A winner will be awarded a diploma and a prize of €500.

10:00 – 11:00 *Special Event*

EAPC General Assembly

11:00 - 12:30 *Symposium*

Chairpersons: Ian Maklim GRAHAM (Wicklow, Ireland), Monique VERSCHUREN (Bilthoven, Netherlands)

**Beyond medicines. Evidence of particular foodstuff for
cardiovascular prevention and management**

11:00 Red rice yeast.

Zeljko REINER (Zagreb, Croatia)

11:22 Cheese and dairy products.

Dag S THELLE (Goteborg, Sweden)

11:45 Soy.

Massimiliano RUSCICA (Milan, Italy)

12:07 Combined nutraceuticals.

Maciej BANACH (Lodz, Poland)

Learning Objectives: Know the pros and cons of nutraceuticals in the prevention of cardiovascular risk factors

11:00 - 12:30 *Symposium*

Chairpersons: Sarah EICHLER (Potsdam, Germany), Guido PIELES (Bristol, United Kingdom)

EAPC Young Community session - New Fields in Preventive Cardiology

11:00 Congenital heart defects and exercise. Promoting health while controlling the risks.

Stefan Sebastian BUSNATU (Bucharest, Romania)

11:22 Cardiac rehabilitation for patients after Mitraclip.

Thomas SCHMIDT (Bad Rothenfelde, Germany)

11:45 A cardiovascular prevention strategy for each age. Building health during each phase of life.

Oksana SIVAKOVA (Moscow, Russian Federation)

12:07 How to interpret the ECG of children practicing sports: can current recommendations be applied in pre-adolescent athletes?

Gavin MCCLEAN (Doha, Qatar)

11:00 - 12:30 *Rapid Fire Abstract*

Rapid Fire session II

Learning Objectives: Fast-paced and interactive session including presentation of 8 topic related abstracts.

Each presentation will be followed by questions and discussions with the audience moderated by the Chairpersons.

12:45 – 13:45 *Satellite Symposium*

Chairpersons: Alain COHEN-SOLAL (Paris, France), Zlatko FRAS (Ljubljana, Slovenia)

New opportunities in cardiac rehabilitation.

12:45 Introduction - New opportunities in cardiac rehabilitation.

Alain COHEN-SOLAL (Paris, France)

12:50 E-health in clinical practice.

Marie-Christine ILIOU (Issy Les Moulineaux Cedex, France)

13:05 New targeted population for cardiac rehabilitation.

Dan GAITA (Timisoara, Romania)

13:20 Optimizing treatments in cardiac rehabilitation.

Maurizio VOLTERRANI (Rome, Italy)

13:40 Conclusion - New opportunities in cardiac rehabilitation.

Alain COHEN-SOLAL (Paris, France)

Learning Objectives: Whereas Cardiac Rehabilitation (CR) originated as an exercise program primarily for middle-aged male patients with coronary heart disease, usually after a myocardial infarction and/or coronary artery bypass surgery, the range of eligible diagnoses and applications for CR has broadened over time. Several telerehabilitation strategies for coronary artery disease and heart failure patients have as a primary aim to improve cardiac patient care, also after the acute cardiac event. Therapeutic strategies could be associated with CR and therefore improve the outcome of cardiovascular.

12:45 – 13:45 *Satellite Symposium*

Chairpersons: Ulf LANDMESSER (Berlin, Germany)

Subtitle: Sponsored by Novartis Pharma AG

Inflammation in atherosclerosis: translating science into practicable solutions.

12:45 Welcome and introduction - Inflammation in atherosclerosis: translating science into practicable solutions.

Ulf LANDMESSER (Berlin, Germany)

12:48 Inflammation in atherosclerosis: translating science into practicable solutions.

Peter LIBBY (Boston, United States of America)

13:08 Clinical residual cardiovascular risk: what are the markers?

Wolfgang KOENIG (Munich, Germany)

13:28 Advancing standard of care in post-myocardial infarction (MI) patients with elevated high sensitivity C-reactive protein (hsCRP).

Discussion

13:43 Summary and closure - Inflammation in atherosclerosis: translating science into practicable solutions.

Ulf LANDMESSER (Berlin, Germany)

Learning Objectives: After this session, participants will be able to understand: · The role of inflammation in atherosclerosis. · That “residual inflammatory risk” is distinct from “residual cholesterol risk” as an independent risk factor for atherosclerosis. · That residual inflammatory risk can be easily diagnosed with available biomarkers – e.g., elevated HsCRP. · The role for tailored therapeutic strategies to reduce residual inflammatory risk and improve outcomes for post-MI patients.

14:00 - 15:30 Symposium

Chairpersons: Zlatko FRAS (Ljubljana, Slovenia), Diederick E GROBBEE (Utrecht, Netherlands)

What is new in the management of people with CHD? EUROASPIRE V survey on cardiovascular disease prevention and diabetes

14:00 New challenges in implementation of CVD prevention in clinical practice.

Kornelia KOTSEVA (London, United Kingdom)

14:22 Lifestyle, blood pressure and lipids management.

Guy DE BACKER (Sint Martens Latem, Belgium)

14:45 Identifying and managing dysglycaemia and diabetes.

Lars RYDEN (Stockholm, Sweden)

15:07 Implications for clinical practice.

David Allan WOOD (London, United Kingdom)

14:00 - 15:30 *How-to Session*

Chairpersons: Marie-Christine ILIOU (Issy Les Moulineaux, France), Heinz VOLLER (Rudersdorf, Germany)

State-of-the-art exercise prescription in patients with cardiovascular disease by the EXPERT tool

14:00 Exercise prescription in cardiovascular patients: do we need an EXPERT tool.

Dominique HANSEN (Hasselt, Belgium)

14:22 Exercise prescription in a case of diabetes with multiple other cardiovascular risk factors.

Josef NIEBAUER (Salzburg, Austria)

14:45 Exercise prescription in a case of coronary artery disease.

Patrick DOHERTY (York, United Kingdom)

15:07 Exercise prescription in a case of heart failure disease.

Frank EDELMANN (Berlin, Germany)

Learning Objectives: The prescription of exercise in rehabilitation should be evidence based. To guarantee a high standard with consideration of modifiers a digital training and decision support system could be a helpful tool

16:30 - 18:00 *Symposium*

Chairpersons: Thomas BERGER (Freistadt, Austria)

**High intensity interval training as a rehabilitation model in
coronary artery disease: what's the evidence?**

16:30 High intensity interval training vs. moderate intensity training: cardiovascular adaptations.

Ole Johan KEMI (Glasgow, United Kingdom)

16:52 High intensity interval training vs. moderate intensity training: CVD risk factors.

Luc VANHEES (Leuven, Belgium)

17:15 Optimal high intensity interval training protocol for cardiac patients.

Philippe MEYER (Geneva, Switzerland)

17:37 High intensity interval training in practice: feasibility, safety, home-based training.

Martin HALLE (Munich, Germany)

Learning Objectives: The symposium will provide an overview of high intensity interval training as a rehabilitation model in coronary artery disease. Enhanced knowledge of the effects of high intensity interval training features on cardiovascular function from healthy to cardiac patients will be introduced. The optimal high intensity interval training protocol as well as safety issues will be discussed.

16:30 - 18:00 *Debate Session*

Chairpersons: Constantinos DAVOS (Athens, Greece), Nathan WONG (Irvine, United States of America)

The obesity debate

16:30 Obesity is a cardiovascular risk factor - PRO.

Constantinos DAVOS (Athens, Greece)

16:52 Obesity is a cardiovascular risk factor - CONTRA.

Wolfram DOEHNER (Berlin, Germany)

17:15 Normal weight obesity and metabolic healthy obesity: clarifications of definitions.

Eberhard STANDL (Munich, Germany)

17:37 Fitness, physical activity and the obesity paradox in coronary heart disease.

Trine MOHOLDT (Trondheim, Norway)

Learning Objectives: This pro and con session should clarify how to handle obesity in different stages of prevention and diagnosis.

16:30 - 18:00 Symposium

Chairpersons: Dirk DE BACQUER (Ghent, Belgium), Demosthenes B PANAGIOTAKOS (Athens, Greece)

Disease management in congestive heart failure and the role of telemedicine.

16:30 Risk modelling in congestive heart failure patients.

Sofie PARDAENS (Ghent, Belgium)

16:52 How Telemedicine might impact on congestive heart failure patients.

Savina NODARI (Brescia, Italy)

17:15 Preventing hospitalizations of congestive heart failure patients through telemonitoring.

Cirila SLEMENIK PUSNIK (Slovenj Gradec, Slovenia)

17:37 HeartMan: the development of a personal decision-support application for the management of heart failure.

Mitja LUSTREK (Ljubljana, Slovenia)

Learning Objectives: Disease management in congestive heart failure (CHF) patients is suboptimal, indicated by insufficient uptake of evidence-based clinical practice guidelines. Home-based management programs using telemonitoring demonstrate improved adherence behaviors and significant clinical improvements in this patient population. This session aims to provide a state of the art overview of risk modelling in CHF, and to outline the role of telemonitoring in improved disease management.

16:30 - 18:00 Young Investigator Awards Abstracts

Young investigator award session IV - Prevention, Epidemiology & Population Science (PEP)

Learning Objectives: Six abstracts selected for their outstanding quality. Finalists will be presenting their research in front of an appreciative audience, chairpersons and judges expert in the topic. A winner will be awarded a diploma and a prize of €500.



Saturday, 21 April 2018



08:30 - 10:00 Symposium

Chairpersons: Constantinos DAVOS (Athens, Greece), Wolfram DOEHNER (Berlin, Germany)

Nutrition in disease and rehabilitation - What do you need to know?

08:30 Nutritional problems in chronic patients - predictor of outcome.

Alessandro LAVIANO (Rome, Italy)

08:52 In-hospital nutritional deficits in elderly patients - how to detect, how to treat?

09:15 Improving nutritional status during rehabilitation; What can we do?

Dan GAITA (Timisoara, Romania)

09:37 Systemic metabolic failure in chronic heart failure: What do we know, what can we do?

Mamas MAMAS (Stockport, United Kingdom)

Learning Objectives: Nutritional aspects and counselling are hidden challenges in cardiac rehabilitation. To comply with the requirement detailed information will be presented in different patient population

08:30 - 10:00 Symposium

Risk estimation: Time to re-think?

08:30 Beyond SCORE: Country specific charts and total events

08:52 Mendelian randomization: the future of precision risk estimation?

09:15 CV Risk Factors and Population Risk in Slovenia.

09:37 Pulling it all together.

08:30 - 10:00 **Symposium**

Chairpersons: Nils REISS (Bad Rothenfelde, Germany)

Cardiac rehabilitation for LVAD patients

08:30 Quality standards for cardiac rehabilitation in LVAD patients.

08:52 Daily activity in LVAD patients - Is there a correlation to exercise testing parameters.

09:15 How to increase physical capacity in LVAD patients.

09:37 Complications and trouble shooting in LVAD patients - What you need to know.

Ugo CORRA (Veruno, Italy)

Learning Objectives: LVAD is a new option to treat end stage heart failure. These patients have a reduced muscle mass, their circulation are not natural. Therefore rehabilitation professionals should be aware of exercise testing parameters, exercise intensity and limitations of exercise capacity.

08:30 - 10:00 **Symposium**

Advanced imaging in athlete's heart

08:30 Speckle tracking echocardiography for assessing right and left ventricular function.

08:52 Characterization of biatrial size and function and implications for supraventricular arrhythmias.

Flavio D'ASCENZI (Siena, Italy)

09:15 Exercise echocardiography: indications and interpretation of findings.

Guido CLAESSEN (Leuven, Belgium)

09:37 Exercise cardiac magnetic resonance: new insights into the assessment of right ventricular function.

Andre LA GERCHE (Melbourne, Australia)

Learning Objectives: To learn how newer imaging technologies may be used for the evaluation and prognostic stratification of athletes.

11:00 - 12:00 **Symposium**

Chairpersons: Ian Maklim GRAHAM (Wicklow, Ireland), Eugenio GRECO (Fuscaldo (Cs), Italy)

Auditing risk factors: not just CHD

11:00 SURF CHD.

11:15 SURF Stroke.

11:30 SURF Chronic obstructive pulmonary disease.

Alexandra DUDINA (Dublin, Ireland)

11:45 SURF Rheumatoid arthritis.

Anne Grete SEMB (Oslo, Norway)

11:00 - 12:00 *Symposium*

Chairpersons: Trine KARLSEN (Bodo, Norway), Hareld KEMPS (Den Bosch, Netherlands)

Atrial fibrillation: a novel target in cardiac rehabilitation?

11:00 Exercise and atrial fibrillation: a complex relation.

Eduard GUASCH (Barcelona, Spain)

11:15 Overweight and atrial fibrillation.

Prashanthan SANDERS (Adelaide, Australia)

11:30 High intensity interval training in patients with atrial fibrillation.

Jan LOENNECHEN (Melhus, Norway)

11:45 Cardiac rehabilitation in patients treated with catheter ablation: results from the CopenHeartRFA trial.

Signe Stelling RISOM (Copenhagen S, Denmark)

Learning Objectives: In recent years, there has been an increasing interest in cardiac rehabilitation as an upstream therapy in atrial fibrillation. In the 2016 ESC guideline on atrial fibrillation, structured support for lifestyle changes including interventions aiming at weight loss and improving exercise capacity are recommended. In this session, the physiological mechanisms underlying the potential benefit of cardiac rehabilitation, as well as results from recent clinical trials will be discussed.

11:00 - 12:00 *Featured Symposium*

Chairpersons: Christian SCHMIED (Zurich, Switzerland)

Controversies in cardiomyopathy management in athletes

11:00 Apical HCM and mild phenotype HCM in athletes: common and benign? Let them play?

Michail PAPADAKIS (London, United Kingdom)

11:20 Hypertrabeculation in athletes - ignore and move on?

Sabiha GATI (London, United Kingdom)

11:40 T-wave inversion on ECG but normal echo. What next?

Frederic SCHNELL (Rennes, France)

11:00 - 12:00 *How-to Session*

Chairpersons: Silvia CASTELLETTI (Milan, Italy), Susana SANS MENENDEZ (Barcelona, Spain)

Subtitle: The European Journal of Preventive Cardiology (EJPC) meets young community

How can I get my research published and recognised?

11:00 Introduction

11:05 Which area of research are most likely to get the interest of the reader in the area of Epidemiology.

11:20 In the area of prevention.

11:35 In the area of Exercise physiology and cardiac rehabilitation.

11:50 Round Table: tips and tricks

12:15 - 13:00 *Special Event*

Chairpersons: Jean-Paul SCHMID (Barmelweid, Switzerland)

Closing Session

12:15 Welcome address.

12:16 Young Investigator Awards.

Jean-Paul SCHMID (Barmelweid, Switzerland)

12:20 Moderated Poster Awards.

Jean-Paul SCHMID (Barmelweid, Switzerland)

12:25 Pantaleo Giannuzzi Award.

Massimo Francesco PIEPOLI (Piacenza, Italy)

12:29 Viviane Conraads outstanding Achievement Award.

12:30 2018 Viviane Conraads Outstanding Achievement Award.


Trine MOHOLDT (Trondheim, Norway)

12:50 EuroPrevent 2019.

Jean-Paul SCHMID (Barmelweid, Switzerland)

12:55 Closing.





Venue:

Cankarjev dom

Cultural and Congress Centre
Presernova cesta 10
1000 Ljubljana
Slovenia
www.cd-cc.si



Organiser:

European Association of Preventive Cardiology (EAPC)



European Society of Cardiology
2035 route des Colles, Les Templiers ,
CS80179 BIOT, 06903 Sophia Antipolis cedex, France
www.escardio.org
Email: europrevent@escardio.org

Key dates:

Abstract Submission deadline:
09 November 2017

Early Registration deadline:
08 February 2018

Late Registration deadline:
15 March 2018

